Alliance Pharma Regulatory News (APH)

8 Aug 2006 07:01

Alliance Pharma PLC08 August 2006 For Immediate Release 8 August 2006 ALLIANCE PHARMA PLC ("Alliance" or "the Company") Notification of Interim Results On behalf of our client Alliance Pharma plc (AIM: APH), the emerging specialitypharmaceutical company, we notify that they will be reporting their InterimsResults for the six months ended 30 June, 2006 on Wednesday 13 September, 2006. For further information: Buchanan Communications + 44 (0) 20 7466 5000 Mark Court/ Rebecca Skye Dietrich Notes to editors About Alliance Pharma Alliance Pharma, founded in 1996, is an AIM listed speciality pharmaceuticalcompany based in Chippenham, Wiltshire, UK. The company has a strong trackrecord of acquiring the rights to established niche brands and owns, or shares,the rights to 32 branded pharmaceutical products and continues to exploreopportunities to expand the range. Alliance Pharma's products are prescribed in the treatment of a wide range ofconditions and include brands used in periodontitis (a serious gum disease), theprevention of heart disease, in Parkinson's disease, in nutrition, in nasalinfections, in the treatment of dermatological conditions and in childbirth.Alliance Pharma's sales are mainly prescription driven. Its products aredistributed to hospitals directly and to UK and International pharmaceuticalwholesalers which service both hospital and retail pharmacies with theirprescription requirements. Alliance Pharma is also developing Posidorm(R) for sleep disorders and Isprelor(R) for the induction of labour. Alliance Pharma joined the AIM market of the London Stock Exchange in December2003 and trades under the symbol APH. This information is provided by RNS The company news service from the London Stock Exchange